Peter Szlosarek, Professor of Medical Oncology at Queen Mary's Barts Cancer Institute, presented his team’s results from the ATOMIC-Meso clinical trial in partnership with Polaris Pharmaceuticals, Inc. The findings show that the new drug, called ADI-